×
About 48,735 results

ALLMedicine™ Diarrhea Center

Research & Reviews  12,493 results

High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflamm...
https://doi.org/10.1093/ibd/izac102
Inflammatory Bowel Diseases; Gold SL, Rabinowitz LG et. al.

May 21st, 2022 - Patients with inflammatory bowel disease (IBD) are at an increased risk of malnutrition. The goal of this study was to define the prevalence of malnutrition and micronutrient deficiencies in recently diagnosed IBD patients and to compare the perfo...

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotro...
https://doi.org/10.1002/14651858.CD006981.pub3
The Cochrane Database of Systematic Reviews; James E, Ellis C et. al.

May 21st, 2022 - Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative condition that may cause dysphagia, as well as limb weakness, dysarthria, emotional lability, and respiratory failure. Since normal s...

Functional bowel symptoms in the general population (Review).
https://doi.org/10.3892/mmr.2022.12742
Molecular Medicine Reports; Ohlsson B

May 21st, 2022 - Several patients with irritable bowel syndrome (IBS) do not seek medical attention for their symptoms. When patients with IBS seek help, the majority of them are handled at primary healthcare centers, whereas research studies are performed at tert...

Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics
https://clinicaltrials.gov/ct2/show/NCT03755765

May 20th, 2022 - Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. One of the most common indications for probiotic treatment is the prevention of antibiotic-associated diarrhea (AAD). Unfortunatel...

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

May 20th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

see more →

Guidelines  17 results

ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides diffici...
https://doi.org/10.14309/ajg.0000000000001278 10.1016/j.cgh.2020.06.051
The American Journal of Gastroenterology; Kelly CR, Fischer M et. al.

May 19th, 2021 - Clostridioides difficile infection occurs when the bacterium produces toxin that causes diarrhea and inflammation of the colon. These guidelines indicate the preferred approach to the management of adults with C. difficile infection and represent ...

AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review.
https://doi.org/10.1053/j.gastro.2020.06.090
Gastroenterology Quigley EM, Murray JA et. al.

Jul 18th, 2020 - Thanks to ready access to hydrogen breath testing, small intestinal bacterial overgrowth is now commonly diagnosed among individuals presenting with a variety of gastrointestinal and even non-gastrointestinal complaints and is increasingly implica...

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
https://doi.org/10.6004/jnccn.2020.0012
Journal of the National Comprehensive Cancer Network : JN... Thompson JA, Schneider BJ et. al.

Mar 7th, 2020 - The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe sympt...

Antimotility agents for the treatment of acute noninfectious diarrhea in critically ill...
https://doi.org/10.1097/TA.0000000000002449
The Journal of Trauma and Acute Care Surgery; Bugaev N, Bhattacharya B et. al.

Oct 2nd, 2019 - Acute noninfectious diarrhea is a common phenomenon in intensive care unit patients. Multiple treatments are suggested but the most effective management is unknown. A working group of the Eastern Association for the Surgery of Trauma, aimed to eva...

Canadian Association of Gastroenterology Clinical Practice Guideline on the Management ...
https://doi.org/10.1016/j.cgh.2019.08.062
Clinical Gastroenterology and Hepatology : the Official C... Sadowski DC, Camilleri M et. al.

Sep 19th, 2019 - Chronic diarrhea affects about 5% of the population overall. Altered bile acid metabolism is a common but frequently undiagnosed cause. We performed a systematic search of publication databases for studies of assessment and management of bile acid...

see more →

Drugs  2,062 results see all →

Clinicaltrials.gov  609 results

Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics
https://clinicaltrials.gov/ct2/show/NCT03755765

May 20th, 2022 - Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. One of the most common indications for probiotic treatment is the prevention of antibiotic-associated diarrhea (AAD). Unfortunatel...

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

May 20th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02673398

May 19th, 2022 - PRIMARY OBJECTIVES: I. To estimate the safety and tolerability of neratinib in adults age 60 or older with locally advanced or metastatic HER2 over-expressing breast cancer. SECONDARY OBJECTIVES: I. To describe the full toxicity profile including ...

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
https://clinicaltrials.gov/ct2/show/NCT04936230

May 19th, 2022 - PRIMARY OBJECTIVE: I. To compare the overall response rates by 6 months in patients with advanced urothelial carcinoma when treated with immunotherapy alone and immunotherapy plus radiotherapy to a single site. SECONDARY OBJECTIVES: I. To compare ...

An Open Label Study in Healthy Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate as Prophylaxis for Development of Severe Viral Illness
https://clinicaltrials.gov/ct2/show/NCT05381454

May 19th, 2022 - Overview of study design Open label clinical trial (intervention with a diet supplement) to evaluate the safety and efficacy of treatment with mitoquinone/mitoquinol mesylate (mito-MES) (20 mg daily) daily to prevent any viral infection in high-ri...

see more →

News  4,058 results

Do COVID Vaccines Stave Off New Medical Conditions?
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/98620

May 9th, 2022 - Risks of long COVID symptoms and the incidence of new onset hypertension, diabetes, and heart disease were lower among vaccinated patients with breakthrough infection versus those with COVID who were unvaccinated, a large analysis of medical recor...

Updates in Treatment of HER2 Mutant NSCLC
https://www.onclive.com/view/updates-in-treatment-of-her2-mutant-nsclc

May 5th, 2022 - Ben Levy, MD: Let’s shift gears to HER2 exon 20, which isn’t to be confused with EGFR exon 20. Not all HER2 is exon 20, but most are. Misako, do you want to walk us through this? We’ve got some very exciting data coming down the pike for these mut...

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors
https://www.onclive.com/view/jdq443-demonstrates-early-efficacy-signals-in-kras-g12c-mutant-solid-tumors

May 2nd, 2022 - The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 (NCT04699188) trial presented at the 2022 AACR Annual Meeting....

Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC
https://www.onclive.com/view/sotorasib-shows-impressive-2-year-os-rate-in-kras-g12c-nsclc

May 2nd, 2022 - Sotorasib (Lumakras) demonstrated an overall survival (OS) rate of 32.5% (95% CI, 25.0%-40.2%) at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC), according to longer follow-up data from the phase 1/2 CodeBreaK 100 tri...

Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer
https://www.onclive.com/view/nab-paclitaxel-plus-pembrolizumab-produces-promising-responses-in-advanced-urothelial-cancer

May 2nd, 2022 - The combination of nab-paclitaxel (Abraxane) and pembrolizumab (Keytruda) produced an encouraging overall response rate (ORR) with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or ...

see more →

Patient Education  255 results see all →